Baseline levels of soluble CD14 and CD16+56- natural killer cells are negatively associated with response to interferon/ribavirin therapy during HCV-HIV-1 coinfection

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 969-973

  Anthony, Donald D ^a   Conry, Sara J ^a   Medvik, Kathy ^a   Sandhya Rani, M R ^b   Falck Ytter, Yngve ^a   Blanton, Ronald E ^b   Lederman, Michael M ^a   Rodriguez, Benigno ^a   Landay, Alan L ^c   Sandberg, Johan K ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD16 ANTIGEN; CD56 ANTIGEN; INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IL28B GENE; IMMUNOSTIMULATION; INNATE IMMUNITY; MALE; MIXED INFECTION; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, CD14; ANTIGENS, CD56; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; MALE; POLYETHYLENE GLYCOLS; RECEPTORS, IGG; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84865733663     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis434     Document Type: Article

References (16)

1. De Maria A, Moretta L. NK cell function in HIV-1 infection. Curr HIV Res 2008; 6:433-40.
2. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60:471-84.
3. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
4. Gonzalez VD, Landay AL, Sandberg JK. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010; 135:12-25.
5. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-30, 1230 e1221-1223.
6. Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823-34.
7. O'Brien TR. Interferon-alfa, interferon-lambda and hepatitis C. Nat Genet 2009; 41:1048-50.
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
9. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
10. Gonzalez VD, Falconer K, Bjorkstrom NK, et al. Expansion of functionally skewed CD56? NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment. J Immunol 2009; 183:6612-8.
11. Conry SJ, Meng Q, Hardy GA, et al. Genetically associated CD16+56? NK-cell IFNaR expression regulates signaling and is implicated in IFNa-induced HCV decline. J Infect Dis 2012; 205:1131-41.
12. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52:1888-96.
13. Hiki N, Berger D, Prigl C, et al. Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria. Infect Immun 1998; 66:1135-41.
14. Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S,Talal AH.Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIVcoinfected patients. J Acquir Immune Defic Syndr 2007; 45:262-8.
15. Lin AW, Gonzalez SA, Cunningham-Rundles S, et al. CD56+dim and CD56 +bright cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 2004; 137:408-16.
16. Marchetti G, Nasta P, Bai F, et al. Circulating sCD14 is associated with virological response to pegylated interferon alpha/ribavirin treatment in HIV/HCV co-infected patients. Plos One 2012; e32028. 10.1371/journal.pone. 0032028.